A decline from baseline in FEV1 of > 15% occurred in 1.3% of EXUBERA-treated type 1 subjects
FEV1 langus > 15% algtasemest esines 1, 3% EXUBERAga ravitud 1. tüüpi diabeediga patsiendil ning 5, 0% EXUBERAga ravitud 2. tüüpi diabeediga patsiendil.